SEATTLE--(BUSINESS WIRE)--Cyrus Biotechnology, Inc., a Seattle-based biotech software company specializing in the use and commercialization of Rosetta, the world's leading computational protein design platform, announces the availability of CryoEM services to generate high precision models from CryoEM data.
“Over the last several years, CryoEM has emerged as the key new structural method across drug discovery, from small molecules to vaccines,” notes Cyrus CEO Dr. Lucas Nivon. “Our customers have been asking for the powerful and complex CryoEM structure determination and refinement capabilities of Rosetta, which we are now providing via consulting services to Cyrus customers.”
Several publications have demonstrated that Rosetta CryoEM refinement yields far better structures than those obtained from other software methods, including key results in Nature Methods and PNAS.
Rosetta offers state-of-the art refinement, model docking into density, and de novo model building for a broad range of CryoEM map resolutions. Combined with demonstrably superior homology modeling predictions, Rosetta can go from map and sequence to full atomic-level accuracy models.
Customers without the resources or expertise to use CryoEM Rosetta structure solution and refinement tools can now take advantage of Cyrus CryoEM Services, which draw from Cyrus in-house expertise from multiple co-authors of these cutting-edge Rosetta/CryoEM methods.
Cyrus CryoEM services include: structure refinement into density, model building de novo, partial model building, and model building with modifications such as carbohydrates. Cyrus partners with leading laboratories to gather CryoEM data if a customer does not have such facilities. Read more at https://cyrusbio.com/cryoem/
Cyrus CryoEM services can be offered immediately. Please contact us to request a proposal: https://cyrusbio.com/request-cryoem-services/
Cyrus Biotechnology, Inc. is a privately held biotechnology software company offering scientific consulting services and the Cyrus Bench® SaaS platform for protein engineering to accelerate discovery of biologics and small molecules for the Biotechnology, Pharmaceutical, Chemical, Consumer Products and Synthetic Biology industries. Cyrus services are based on the Rosetta software from Prof. David Baker’s laboratory at the University of Washington. Rosetta is the most powerful protein engineering software available. Cyrus customers include 13 of the top 20 Global Pharmaceutical firms. The company is financed by leading investors in both Technology and Biotechnology, including Trinity Ventures, Orbimed, Springrock Ventures, Alexandria Venture Investments, and W Fund. https://cyrusbio.com/